Funders · Entity Annotation Prototype (beta)

1articles mentioning funders

1funder mentions

1distinct funders extracted

0%of mentions human-reviewed

Active filtersEntity: ID TJ-IRB202412051-1 ×

ID TJ-IRB202412051-1

This funder is selected. Its supporting articles are shown below.

ID TJ-IRB202412051-11

Articles mentioning ID TJ-IRB202412051-1

1 articles · page 1 of 1

545 A Phase 1 study evaluating the safety, tolerability, and preliminary efficacy of IB-T101, an OUTLAST™-conditioned CD70-targeted CAR-T cell therapy, in patients with clear cell renal cell carcinoma

jitc · abstract · 2025-11-04 · 1 matching annotations

75.3%

Tongji Hospital Medical Ethics Committee ID TJ-IRB202412051-1 IB-T101 ccRCC OUTLAST™ conditioning hematologic malignancies

…ration NCT06819293Ethics Approval The study was approved by the Tongji Hospital Medical Ethics Committee, ID TJ-IRB202412051-1. Study participants gave informed consent…

Browse funders

ID TJ-IRB202412051-1

Articles mentioning ID TJ-IRB202412051-1

545 A Phase 1 study evaluating the safety, tolerability, and preliminary efficacy of IB-T101, an OUTLAST™-conditioned CD70-targeted CAR-T cell therapy, in patients with clear cell renal cell carcinoma